SGLT2 inhibitors and GLP1 agonists not cost-effective as first-line therapies

Time : 6th of October 2022 10:22:19 AM

A study says that prices of these drugs should drop by a minimum of 70% for them to become cost-effective as first-line anti-diabetic therapies in the US. The underlying reasons for their poor cost-effectiveness compared to first-line metformin therapy are the lower QoL due to injections and higher prices. But, these drugs had the benefits of lower macrovascular complications.

  Medwire News


first-line, anti-diabetic, SGLT2, GLP1, metformin

Recent Posts

Can a person live without the pancreas?
8th of December 2022 01:18:42 PM

Are COVID-19 vaccines effective against long Covid?
8th of December 2022 11:40:20 AM

Cancer regression without treatment is very rare
8th of December 2022 09:40:03 AM

Rebound of COVID-19 after Paxlovid treatment is rare
7th of December 2022 01:05:16 PM